NT 175 - Neogene Therapeutics
Alternative Names: NT-175Latest Information Update: 09 Jul 2024
At a glance
- Originator Neogene Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 31 May 2024 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 17 Jul 2023 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT05877599)
- 26 May 2023 Neogene Therapeutics plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA in August 2023 (NCT05877599)